Novo Nordisk’s Q3 2024 Earnings: Wegovy Wins Big While Diabetes Drug Faces Competition

TradingKey - In the world of healthcare and pharmaceuticals, Novo Nordisk A/S (NYSE: NVO) is a recognisable name. The Danish drugs giant – know for its diabetes and obesity treatments – recently reported its Q3 2024 earnings. 

The results highlighted the company’s ability to grow revenue and profits, even as its two flagship products (Wegovy and Ozempic) faced varying market dynamics.

Revenue and profit jump despite minor miss

In the third quarter, Novo Nordisk posted revenue of DKK 71.3 billion (US$10.3 billion), a 21% increase year-on-year, although this figure came in just below analysts' expectations of DKK 72.3 billion. 

Despite the revenue miss, Novo’s operating profit surged by 26% to reach DKK 33.8 billion, underscoring the company’s efficiency in managing expenses and maximising its revenue streams. 

Year-to-date operating profits in 2024 also climbed by 18% to DKK 91.6 billion. This sustained growth trend in both revenue and profitability reflects the company’s strategic approach to meet rising demand for its treatments. It also highlights its ability to manage costs and production challenges.

The strong Q3 2024 earnings led Novo Nordisk to raise its full-year forecast for both sales and operating profit, now expecting annual growth of between 23%-27% and 21%-27%, respectively, on a currency-adjusted basis. 

This revised positive outlook reflects Novo’s confidence in the momentum it has built and its capacity to meet continued demand for its blockbuster drugs.

Wegovy shines in the obesity market

Novo’s weight-loss drug Wegovy was the standout performer for the quarter, significantly exceeding expectations. Sales for Wegovy came in at DKK 17.3 billion, surpassing analyst projections of DKK 15.9 billion. 

This represents an impressive 79% year-on-year growth rate, driven largely by demand in North America. The weight-loss market in the region has expanded rapidly, with Wegovy capturing a significant share as obesity treatments continue to become a higher priority for healthcare providers and patients alike.

For the first nine months of 2024, Wegovy’s sales reached DKK 38.3 billion, marking a 76% annual increase. This growth reflects Novo Nordisk’s strategic push to expand availability and increase production capacity to meet the soaring demand. 

Ozempic faces competitive pressures

While Wegovy experienced a quarter of remarkable growth, Novo Nordisk’s diabetes treatment, Ozempic, faced a more challenging environment. 

Ozempic’s Q3 2024 sales grew by 26% year-on-year to reach DKK 29.8 billion. Although this figure was strong, it came in slightly below analysts’ expectations due to pricing pressures and supply constraints in North America, where competition in the diabetes and obesity drug markets has been heating up.

One of the main factors influencing Ozempic’s market dynamics is the introduction of Eli Lilly & Co’s (NYSE: LLY)’s GLP-1 drug – Zepbound – which provides an alternative for patients seeking similar treatment outcomes. 

Eli Lilly’s entry into the market has heightened competition, particularly in the US, where both companies are vying for the growing pool of diabetes and weight management patients.

Strategic investments to meet growing demand

Novo Nordisk’s updated forecast and increased production efforts underscore its commitment to long-term growth in the GLP-1 treatment market. 

Recognising the soaring demand for Wegovy and Ozempic, the company has been ramping up production capacity, with a focus on alleviating supply constraints that have occasionally limited availability in some regions. 

This investment in scaling production capacity is not only aimed at supporting current demand but also positioning Novo to capture a larger share of the growing diabetes and obesity markets in the years to come.